- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Ipsen SA ADR (IPSEY)
Ipsen SA ADR stock price live, this page displays OTC IPSEY stock exchange data. View the IPSEY premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Ipsen SA ADR real time stock price chart below.
What Is the Ipsen SA ADR Stock Price Today?
The Ipsen SA ADR stock price today is 46.750.
What Is the Stock Symbol for Ipsen SA ADR?
The stock symbol for Ipsen SA ADR is "IPSEY."
What Stock Exchange Does Ipsen SA ADR Trade On?
Ipsen SA ADR is listed and trades on the OTC Markets stock exchange.
Is Ipsen SA ADR a Good Stock to Buy?
Determining whether Ipsen SA ADR—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the IPSEY quote. (ISIN: US4626292050)
What Is the Ipsen SA ADR Stock Price Today?
The Ipsen SA ADR stock price today is 46.750.
What Is the Stock Symbol for Ipsen SA ADR?
The stock symbol for Ipsen SA ADR is "IPSEY."
What Stock Exchange Does Ipsen SA ADR Trade On?
Ipsen SA ADR is listed and trades on the OTC Markets stock exchange.
Is Ipsen SA ADR a Good Stock to Buy?
Determining whether Ipsen SA ADR—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the IPSEY quote. (ISIN: US4626292050)
46.750
0.000(0.00%)
Delayed Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
45.615
46.750
52 wk Range
28.655
51.100
IPSEY is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
45.61546.750
52 wk Range
28.65551.100
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(0.72%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(0.72%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
IPSEY Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
RSI suggests the stock is in overbought territory
- Ipsen receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Ipsen receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Buy
Moving Averages
Strong Buy
Earnings
Latest Release
Apr 23, 2026
EPS / Forecast
-- / --
Revenue / Forecast
1,26B / 1,17B
Compare IPSEY to Peers and Sector
Metrics to compare | IPSEY | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipIPSEYPeersSector | |
|---|---|---|---|---|
P/E Ratio | 29.1x | 24.6x | −0.5x | |
PEG Ratio | 1.04 | 0.50 | 0.00 | |
Price/Book | 3.0x | 5.0x | 2.6x | |
Price / LTM Sales | 3.3x | 3.9x | 3.0x | |
Upside (Analyst Target) | - | 15.9% | 58.6% | |
Fair Value Upside | Unlock | 13.3% | 10.2% | Unlock |
Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience in North America, Europe, and internationally. Its oncology products include Somatuline for the treatment of neuroendocrine tumors; Cabometyx, a tyrosine kinase inhibitor to treat advanced tumor that affecting kidney; Onivyde, an irinotecan liposome injection for the treatment of metastatic pancreatic adenocarcinoma; Somatuline Autogel for the treatment of neuroendocrine tumors; and Ojemda, a Type II RAF kinase inhibitor of BRAF that is in phase III clinical trial for the treatment of pediatric low-grade glioma tumor. It also develops IPN01195, IPN60300, and IPN01203, which are in phase I clinical trial for the treatment of solid tumors; and IPN60340, BTN3A T cell activator that is in Phase II clinical trial for the treatment of acute myeloid leukemia. In addition, the company develops products for rare disease comprising Bylvay for the treatment of Biliary atresia; Iqirvo, a peroxisome proliferator-activated receptor agonist to treat primary biliary cholangitis; and Elafibranor, a peroxisome proliferator-activated receptor a/d agonist for the treatment of primary sclerosing cholangitis. Further, it develops Corabotase, a recombinant neuroinhibitory for the treatment of glabellar, forehead, and lateral canthal lines; adult upper limb spasticity; migraine; cervical dystonia; and chronic and episodic migraine diseases. Ipsen S.A. was founded in 1929 and is headquartered in Paris, France.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Ipsen ADR (IPSEY) Stock Price Today?
The Ipsen ADR stock price today is 46,750 USD.
What Stock Exchange Does Ipsen ADR Trade On?
Ipsen ADR is listed and trades on the OTC Markets.
What Is the Stock Symbol for Ipsen ADR?
The stock symbol for Ipsen ADR is "IPSEY."
Does Ipsen ADR Pay Dividends? What’s The Current Dividend Yield?
The Ipsen ADR dividend yield is 0.72%.
What Is the Ipsen ADR Market Cap?
As of today, Ipsen ADR market cap is 14,940B USD.
What Is Ipsen ADR's Earnings Per Share (TTM)?
The Ipsen ADR EPS (TTM) is 5,320.
When Is the Next Ipsen ADR Earnings Date?
Ipsen ADR will release its next earnings report on Jul 30, 2026.
From a Technical Analysis Perspective, Is IPSEY a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has Ipsen ADR Stock Split?
Ipsen ADR has split 0 times.
How Many Employees Does Ipsen ADR Have?
Ipsen ADR has 5535 employees.
What is the current trading status of Ipsen ADR (IPSEY)?
As of Jun 12, 2026, Ipsen ADR (IPSEY) is trading at a price of 46,750 USD, with a previous close of 46,750 USD. The stock has fluctuated within a day range of 45,615 USD to 46,750 USD, while its 52-week range spans from 28,655 USD to 51,100 USD.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.